Market Access News | pharmaphorum

News

FDA maps new regulatory route for ultra-rare diseases

The FDA has sketched out its 'plausible mechanism' regulatory pathway for individualised therapies that treat ultra-rare diseases.

News

FDA clears first all-oral combo for first-line CLL treatment

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

News

What next for pharma as SCOTUS strikes down Trump tariffs?

The centrepiece of President Trump's economic strategy has been shattered after the Supreme Court ruled his sweeping tariffs are illegal.

News

FDA starts review of Regeneron's drug for rare disease FOP

Can Regeneron's drug for ultra-rare bone disease FOP pick up the baton from Ipsen's Sohonos, whose growth has stalled?

News

Woman on crutches, left-hand side of her body, face not revealed

UK firm steps in to ease medicine supply crisis in NHS

Amid reports that a shortage of bone cement in the UK is leading to delayed orthopaedic surgeries, Biocomposites has brought forward a product launch.

News

Texas sues Sanofi, claiming kickbacks to doctors

Texas Attorney General Ken Paxton has filed a lawsuit against Sanofi, claiming the company bribed doctors to prescribe its medicines.

FDA maps new regulatory route for ultra-rare diseases

FDA clears first all-oral combo for first-line CLL treatment

What next for pharma as SCOTUS strikes down Trump tariffs?

FDA starts review of Regeneron's drug for rare disease FOP

UK firm steps in to ease medicine supply crisis in NHS

Texas sues Sanofi, claiming kickbacks to doctors

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks